18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial - The Lancet

Frontiers PET/CT-Based Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy: Impact on Treatment Management and Future Directions

Cancers, Free Full-Text

Impact of 18F-fluciclovine PET/CT on plans for androgen deprivation therapy in patients with biochemical recurrence of prostate cancer: data analysis from two prospective clinical trials - ScienceDirect

Radiotherapy in Prostate Cancer: Utilization of Adjuvant and Salvage Radiotherapy

Axumin LOCATE Trial Results Axumin® (fluciclovine F 18) Injection

PSMA PET/CT guided intensification of therapy in patients at risk of advanced prostate cancer (PATRON): a pragmatic phase III randomized controlled trial, BMC Cancer

Clinical practice in prostate PET imaging - Sean J. Huls, Brian Burkett, Eric Ehman, Val J. Lowe, Rathan M. Subramaniam, A. Tuba Kendi, 2023

Cancers, Free Full-Text

Clinical practice in prostate PET imaging - Sean J. Huls, Brian Burkett, Eric Ehman, Val J. Lowe, Rathan M. Subramaniam, A. Tuba Kendi, 2023

PSMA guided approach for bIoCHEmical relapse after prostatectomy‐ (PSICHE) trial (NCT05022914). Detection rate and treatment decision after 68Ga‐PSMA PET/CT within a prospective study - Francolini - 2023 - The Prostate - Wiley Online Library

Improvements in Prostate Cancer Management: Focus on Imaging and Treatment - European Medical Journal

PDF) Impact of 18F-fluciclovine PET/CT on salvage radiotherapy plans for men with recurrence of prostate cancer postradical prostatectomy